0000000000685422

AUTHOR

Mary V. Seeman

showing 1 related works from this author

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

2017

Marco Solmi,1,2 Andrea Murru,3 Isabella Pacchiarotti,3 Juan Undurraga,4,5 Nicola Veronese,2,6 Michele Fornaro,7,8 Brendon Stubbs,2,9–11 Francesco Monaco,2 Eduard Vieta,3 Mary V Seeman,12 Christoph U Correll,13,14 André F Carvalho2,15 1Neuroscience Department, University of Padua, 2Institute for Clinical Research and Education in Medicine, Padua, Italy; 3Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; 4Department of Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo, 5Early Intervention Program, J. Horwitz Psychiatric Institute, Santiago, Chile; 6Na…

Olanzapinesafetymedicine.medical_specialtyside effectToxicology and Pharmaceutics (all)ReviewRM1-950psychosi03 medical and health sciencesIloperidonechemistry.chemical_compound0302 clinical medicineSertindoleJournal ArticlemedicineAsenapinePharmacology (medical)psychosisGeneral Pharmacology Toxicology and PharmaceuticstolerabilityPsychiatryLurasidoneBrexpiprazolePharmacologyChemical Health and Safetybusiness.industryMedicine (all)Transtornos PsicóticosGeneral Medicinepsychiatry3. Good health030227 psychiatryantipsychotics side effects tolerability safety psychosis psychiatryantipsychoticantipsychoticsside effectsPsychotic DisordersTolerabilitychemistryQuetiapineAntipsychotics; Psychiatry; Psychosis; Safety; Side effects; Tolerability; Medicine (all); Safety Research; Pharmacology Toxicology and Pharmaceutics (all); Chemical Health and Safety; Pharmacology (medical)Therapeutics. PharmacologyAntipsicóticosbusinessSafety Research030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugTherapeutics and Clinical Risk Management
researchProduct